Molecular weight (DA)
79kD
Immunogen
The antiserum was produced against synthesized peptide derived from human BARD1. AA range:1-50
Specificity
BARD1 Polyclonal Antibody detects endogenous levels of BARD1 protein.
Formulation
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Dilution rate
WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/5000.. IF 1:50-200
Purification process (Immunogen)
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Background
This gene encodes a protein which interacts with the N-terminal region of BRCA1. In addition to its ability to bind BRCA1 in vivo and in vitro, it shares homology with the 2 most conserved regions of BRCA1: the N-terminal RING motif and the C-terminal BRCT domain. The RING motif is a cysteine-rich sequence found in a variety of proteins that regulate cell growth, including the products of tumor suppressor genes and dominant protooncogenes. This protein also contains 3 tandem ankyrin repeats. The BARD1/BRCA1 interaction is disrupted by tumorigenic amino acid substitutions in BRCA1, implying that the formation of a stable complex between these proteins may be an essential aspect of BRCA1 tumor suppression. This protein may be the target of oncogenic mutations in breast or ovarian cancer. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gen
Function
caution:It is uncertain whether Met-1 or Met-26 is the initiator.,disease:Defects in BARD1 gene are found in primary breast, ovarian and uterine cancers.,function:The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Plays a central role in the control of the cell cycle in response to DNA damage. Acts by mediating ubiquitin E3 ligase activity that is required for its tumor suppressor function. Also forms a heterodimer with CSTF1/CSTF-50 to modulate mRNA processing and RNAP II stability by inhibiting pre-mRNA 3' cleavage.,pathway:Protein modification; protein ubiquitination.,PTM:Processed during apoptosis. The homodimer is more susceptible to proteolytic cleavage than the BARD1/BRCA1 heterodimer.,similarity:Contains 1 RING-type zinc finger.,similarity:Contains 2 B
Protein name
BRCA1-associated RING domain protein 1
Other name
BARD1; BRCA1-associated RING domain protein 1; BARD-1
Fields
>>Homologous recombination
Human protein sequence Database
Q99728
Mouse protein sequence database
O70445
Rat protein sequence database
Cellular localization
Nucleus. During S phase of the cell cycle, colocalizes with BRCA1 into discrete subnuclear foci. Can translocate to the cytoplasm. Localizes at sites of DNA damage at double-strand breaks (DSBs); recruitment to DNA damage sites is mediated by the BRCA1-A complex.
Tissue expression
B-cell,Brain,
Contract Us
Follow Us
Location： 
Specification
成功添加到购物车